Skip to main content
SpringerLink
Log in

n-3 Polyunsaturated fatty acids in the treatment of patients with IgA nephropathy

  • Chapter
Medicinal Fatty Acids in Inflammation

Part of the book series: Progress in Inflammation Research ((PIR))

Abstract

First described in 1968 by Berger and Hinglais [1], immunoglobulin A nephropathy (IgAN) is now recognized as the most commonly encountered primary glomerulonephritis worldwide [2-4]. IgAN is an immune complex-mediated glomerular disease defined morphologically by the constant presence of predominant or codominant mesangial deposits of IgA accompanied by a variety of proliferative and/or sclerosing histopathologic lesions [5]. IgAN is characterized by a highly variable clinical course with many patients developing a chronic, slowly progressive decline in renal function over 10–20 years [6-12]. Due to a poorly understood pathogenesis, and because of the variability of the disease, it has been difficult to determine optimal therapy for patients with IgAN [13]. To provide rationale for novel therapeutic agents capable of preserving renal function, there has been active interest in elucidating histopathologic features that confer a high risk of disease progression in patients with IgAN.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Berger J, Hinglais N (1968) Les depots intercapillaires d’IgA - IgG. J Urol Nephrol 74: 694–695

    CAS  Google Scholar 

  2. Sinniah R, Javier AR, Ku G (1981) The pathology of mesangial IgA nephritis with clinical correlation. Histopathology 5: 469–490

    Article  PubMed  CAS  Google Scholar 

  3. D’Amico G (1987) The commonest glomerulonephritis in the world: IgA nephropathy. Q J Med 245: 709–727

    Google Scholar 

  4. Julian BA, Waldo B, Rifai A, Mestecky J (1988) IgA nephropathy, the most common glomerulonephritis worldwide. Am J Med 84: 129–132

    Article  PubMed  CAS  Google Scholar 

  5. Donadio JV, Grande JP (1997) Immunoglobulin A nephropathy: A clinical perspective. J Am Soc Nephrol 8: 1324–1332

    PubMed  Google Scholar 

  6. Hood SA, Velosa JA, Holley KE, Donadio JV (1981) IgA-IgG nephropathy: Predictive indices of progressive disease. Clin Nephrol 16: 55–62

    PubMed  CAS  Google Scholar 

  7. Droz D (1976) Natural history of primary glomerulonephritis with mesangial deposits of IgA. Contrib Nephrol 2: 150–157

    Google Scholar 

  8. Droz D, Kramar A, Nawar T, Noel LH (1984) Primary IgA nephropathy: Prognostic factors. Contrib Nephrol 40: 202–207

    PubMed  CAS  Google Scholar 

  9. Schmekel B, Svalander C, Bucht H, Westberg NG (1981) Mesangial IgA glomerulonephritis in adults. Acta Med Scand 210: 363–372

    Article  PubMed  CAS  Google Scholar 

  10. Lee S-MK, Rao VM, Franklin WA, Schiffer MS, Aronson AJ, Spargo BH, Katz AI (1982) IgA nephropathy: Morphologic predictors of progressive renal disease. Hum Pathol 13: 314–322

    Article  PubMed  CAS  Google Scholar 

  11. Radford MG, Donadio JV, Bergstralh EJ, Grande JP (1997) Predicting renal outcome in IgA nephropathy. J Am Soc Nephrol 8: 199–207

    Google Scholar 

  12. Ibels LS, Gyory AZ (1994) IgA nephropathy: Analysis of the natural history, important factors in the progression of renal disease, and a review of the literature. Medicine 73: 79–102

    Article  PubMed  CAS  Google Scholar 

  13. Feehally J (1994) Strategies for the management of IgA nephropathy. In: Annual Yearbook of Nephrology, Dialysis and Transplantation. Oxford University Press, Oxford, UK, 23–29.

    Google Scholar 

  14. Emancipator SN, Lamm ME (1989) IgA nephropathy: Pathogenesis of the most common form of glomerulonephritis. Lab Invest 60: 168–183

    PubMed  CAS  Google Scholar 

  15. Frohnert PP, Donadio JV, Velosa JA, Holley KE, Sterioff S (1997) The fate of renal transplants in patients with IgA nephropathy. Clin Transplant 11: 127–133

    PubMed  CAS  Google Scholar 

  16. Berger J (1983) Studies on mesangial IgA glomerulonephritis. Kidney Int 24: 408

    Article  Google Scholar 

  17. Coppo R, Emancipator S (1994) Pathogenesis of IgA nephropathy: Established observations, new insights and perspectives in treatment. J Nephrol 7: 5–15

    Google Scholar 

  18. McCoy RC, Abramowsky CR, Tisher CC (1974) IgA nephropathy. Am J Pathol 76: 123–144

    PubMed  CAS  Google Scholar 

  19. Silva FG (1988) Overview of pediatric nephropathology. Kidney Int 33: 1016–1032

    Article  PubMed  CAS  Google Scholar 

  20. Rodicio JL (1984) Idiopathic IgA nephropathy. Kidney Int 25: 717–729

    Article  PubMed  CAS  Google Scholar 

  21. Couser WG (1985) Mechanisms of glomerular injury in immune complex disease. Kidney Int 28: 569–583

    Article  PubMed  CAS  Google Scholar 

  22. Emancipator SN, Lamm ME (1987) The role of IgG, IgM, and C3 in experimental murine IgA nephropathy. Semin Nephrol 7: 286–288

    PubMed  CAS  Google Scholar 

  23. Emancipator SN, Ovary Z, Lamm ME (1987) The role of mesangial complement in the hematuria of experimental IgA nephropathy. Lab Invest 57: 269–276

    PubMed  CAS  Google Scholar 

  24. Cochrane CG, MullerEberhard HJ, Aikin BS (1970) Depletion of plasma complement in vivo by a protein of cobra venom: Its effect on various immunologic reactions. J Immunol 105: 55–69

    PubMed  CAS  Google Scholar 

  25. Habib RB, Stork JE, Emancipator SN (1987) Complement on immune complexes (IC) or zymosan (Z) stimulates prostaglandin (PG) E2 synthesis by glomeruli and cultured glomerular epithelial cells. Fed Proc 46: 1329

    Google Scholar 

  26. Stork JE, Dunn MJ, Emancipator SN (1985) Identification of complement receptor (CRI) on rat glomerular cells: Effects of complement on prostaglandin synthesis. Clin Res 33: 589

    Google Scholar 

  27. Sedor JR, Carey SW, Emancipator SN (1987) Immune complexes bind to cultured rat glomerular mesangial cells to stimulate superoxide release. J Immunol 138 (11): 3751–3757

    PubMed  CAS  Google Scholar 

  28. Lovett DH, Szamel M, Ryan JL, Sterzel RB, Gemsa D, Resch K (1986) Interleukin 1 and the glomerular mesangium. I. Purification and characterization of a mesangial cell-derived auto-growth factor. J Immunol 136: 3700–3705

    PubMed  CAS  Google Scholar 

  29. Scharschmidt LA, Lianos E, Dunn MJ (1983) Arachidonate metabolites and the control of glomerular function. Fed Proc 42: 3058–3063

    PubMed  CAS  Google Scholar 

  30. Werber HI, Emancipator SN, Tykocinski ML, Sedor JR (1987) The interleukin 1 gene is expressed by rat glomerular mesangial cells and is augmented in immune complex glomerulonephritis. J Immunol 138: 3207–3212

    PubMed  CAS  Google Scholar 

  31. Schlondorff D, Satriano JA, Hagege J, Perez J, Baud L (1984) Effect of platelet-activating factor and serum-treated zymosan on prostaglandin E2 synthesis, arachidonic acid release, and contraction of cultured rat mesangial cells. J Clin Invest 73: 1227–1231

    Article  PubMed  CAS  Google Scholar 

  32. Baud L, Hagege J, Sraer J, Rondeau E, Perez J, Ardaillou R (1983) Reactive oxygen production by cultured rat glomerular mesangial cells during phagocytosis is associated with stimulation of lipoxygenase activity. J Exp Med 158: 1836–1852

    Article  PubMed  CAS  Google Scholar 

  33. Emancipator SN, Rao CS, Amore A, Coppo R, Nedrud JC (1992) Macromolecular properties that promote mesangial binding and mesangiopathic nephritis. J Am Soc Nephrol 2: S149–S158

    CAS  Google Scholar 

  34. Amore A, Cavallo F, Bocchietto E, Bussolino F, Gianoglio B, Peruzzi L, Porcellini MG, Coppo R (1993) Cytokine mRNA expression by cultured rat mesangial cells after contact with ehvironmental lectins. Kidney Int 43: S41–546

    Google Scholar 

  35. Mustonen J, Pasternack A, Helin H, Nikkila M (1985) Clinicopathologic correlations in a series of 143 patients with IgA glomerulonephritis. Am J Nephrol 5: 150–157

    Article  PubMed  CAS  Google Scholar 

  36. Kobayashi Y, Tateno S, Hiki Y, Shigematsu H (1983) IgA nephropathy: Prognostic significance of proteinuria and histological alterations. Nephron 34: 146–153

    Article  PubMed  CAS  Google Scholar 

  37. Velo M, Lozano L, Egido J, Gutierrez-Millet V, Hernando L (1987) Natural history of IgA nephropathy in patients followed up for more than ten years in Spain. Semin Nephrol 7: 346–350

    PubMed  CAS  Google Scholar 

  38. Abe T, Kida H, Yoshimura M et al (1986) Participation of extracapillary lesions (ECL) in progression of IgA nephropathy. Clin Nephrol 25: 37–41

    PubMed  CAS  Google Scholar 

  39. Donadio JV, Bergstralh EJ, Offord KP, Holley KE, Spencer DC (1994) Clinical and histopathologic associations with impaired renal function in IgA nephropathy. Clin Nephrol 41: 65–71

    PubMed  CAS  Google Scholar 

  40. Haas M (1997) Histologic subclassification of IgA nephropathy: A clinicopathologic study of 244 cases. Am J Kidney Dis 29: 829–842

    Article  PubMed  CAS  Google Scholar 

  41. Woodroffe AJ, Bannister KM, Bellon MS, Hale GM, Clarkson AR (1987) Do local hemodynamic alterations mediate injury in IgA nephropathy? Semin Nephrol 7: 341–343

    PubMed  CAS  Google Scholar 

  42. Alamartine E, Sabatier JC, Berthoux FC (1990) Comparison of pathological lesions on repeated renal biopsies in 73 patients with primary IgA glomerulonephritis: Value of quantitative scoring and approach to final prognosis. Clin Nephrol 34: 45–51

    PubMed  CAS  Google Scholar 

  43. D’Amico G, Minetti L, Ponticelli C, Fellin G, Ferrario F, Di Belgioioso GB, Imbasciati E, Ragni A, Bertoli S, Fogazzi G et al (1986) Prognostic indicators in idiopathic IgA mesangial nephropathy. Q J Med 228: 363–378

    Google Scholar 

  44. Alamartine E, Sabatier J-C, Guerin C, Berliet J-M, Berthoux F (1991) Prognostic factors in mesangial IgA glomerulonephritis: An extensive study with univariate and multivariate analysis. Am J Kidney Dis 18: 12–19

    PubMed  CAS  Google Scholar 

  45. Chida Y, Tomura S, Takeuchi J (1985) Renal survival rate of IgA nephropathy. Nephron 40: 189–194

    Article  PubMed  CAS  Google Scholar 

  46. Gallo GR, Katafuchi R, Neelakantappa K, Baldwin DS (1988) Prognostic pathologic markers in IgA nephropathy. Am J Kidney Dis 12: 362–365

    PubMed  CAS  Google Scholar 

  47. Neelakantappa K, Gallo GR, Baldwin DS (1987) Proteinuria in IgA nephropathy. Semin Nephrol 7: 344–345

    PubMed  CAS  Google Scholar 

  48. Donadio JV (1991) Omega-3 polyunsaturated fatty acids: A potential new treatment of immune renal disease. Mayo Clin Proc 66: 1018–1028

    Article  CAS  Google Scholar 

  49. Donadio JV (1993) An overview of n-3 fatty acids in clinical renal diseases. In: R De Caterina, S Endres, SD Kristensen, EB Schmidt (eds): Current topics in cardiovascular disease. 1st ed. Bi & Gi Publishers, Verona, Italy, 123–132

    Google Scholar 

  50. Sakr HM, Dunham EW (1982) Mechanism of arachidonic acid-induced vasoconstriction in the intact rat kidney: possible involvement of thromboxane A2. J Pharmacol Exp Ther 221: 614–622

    PubMed  CAS  Google Scholar 

  51. Endoh M, Kashem A, Yamauchi F, Yano N, Nomoto Y, Sakai H, Kurokawa K (1997) Expression of thromboxane synthase in kidney tissues from patients with IgA nephropathy. Clin Nephrol 47: 168–175

    PubMed  CAS  Google Scholar 

  52. Rifai A, Sakai H, Yagame M (1993) Expression of 5-lipoxygenase and 5-lipoxygenase activation protein in glomerulonephritis. Kidney Int 39: S95–S99

    CAS  Google Scholar 

  53. Turi S, Nagy J, Haszon I, Havass Z, Nemeth M, Bereczki C (1988) Disturbances of lipoprotein and PGI2 metabolism in IgA nephropathy and Henoch-Schönlein purpura. Contrib Nephrol 67: 37–43

    PubMed  CAS  Google Scholar 

  54. Fischer S, Weber PC (1984) Prostaglandin 13 is formed in vivo in man after dietary eicosapentaenoic acid. Nature 307: 165–168

    Article  PubMed  CAS  Google Scholar 

  55. Fischer S, Weber PC (1983) Thromboxane A3 (TXA3) is formed in human platelets after dietary eicosapentaenoic acid (C20: 5 omega 3). Biochem Biophys Res Commun 116: 1091–1099

    Article  PubMed  CAS  Google Scholar 

  56. Lee TH, Mencia-Huerta J-M, Corey EJ, Lewis RA, Austen KF (1984) Effects of exogenous arachidonic, eicosapentaenoic, and docosahexaenoic acids on the generation of 5lipoxygenase pathway products by ionophore-activated human neutrophils. J Clin Invest 74: 1922–1933

    Article  PubMed  CAS  Google Scholar 

  57. Weaver BJ, Holub BJ (1988) Health effects and metabolism of dietary eicosapentaenoic acid. Prog Food Nutr Sci 12: 111–150

    PubMed  CAS  Google Scholar 

  58. Spurney RF, Ruiz P, Albrightson CR, Pisetsky DS, Coffman TM (1994) Fish oil feeding modulates leukotriene production in murine lupus nephritis. Prostaglandins 48: 331–348

    Article  PubMed  CAS  Google Scholar 

  59. Milner LS, Wei S, Kazakoff P, Watkins L, Houser MT (1994) Synergistic effects of fish oil diet and dimethylthiourea in acute adriamycin nephrosis. Am J Med Sci 308: 266–270

    Article  PubMed  CAS  Google Scholar 

  60. Yokoyama H, Takaeda M, Wada T, Ogi M, Tomosugi N, Takabatake T, Abe T, Yoshimura M, Kida H, Kobayashi K (1992) Intraglomerular expression of MHC class II and Ki-67 antigens and serum gamma-interferon levels in IgA nephropathy. Nephron 62: 169–175

    Article  PubMed  CAS  Google Scholar 

  61. Bruno S, Crissman HA, Bauer KD, Darzynkiewicz Z (1991) Changes in cell nuclei during S phase: Progressive chromatin condensation and altered expression of the proliferation associated nuclear proteins Ki-67, cyclin (PCNA), p105, and p34. Exp Cell Res 196: 99–106

    Article  PubMed  CAS  Google Scholar 

  62. Endres S, Ghorbani R, Kelley VE, Georgilis K, Lonnemann G, van der Meer JWM, Cannon JG, Rogers TS, Klempner MS, Weber PC et al (1989) The effect of dietary supplementation with n-3 polyunsaturated fatty acids on the synthesis of interleukin-1 and tumor necrosis factor by mononuclear cells. N Engl J Med; 320: 265–271

    Article  PubMed  CAS  Google Scholar 

  63. Tessier C, Fayard J-M, Cohen H, Pageaux J-F, Lagarde M, Laugier C (1995) Docosahexaenoic acid is a potent inhibitor of rat uterine stromal cell proliferation. Biochem Biophys Res Commun 207: 1015–1021

    Article  PubMed  CAS  Google Scholar 

  64. Chandrasekar B, Fernandes G (1994) Decreased pro-inflammatory cytokines and increased antioxidant enzyme gene expression by ω–3 lipids in murine lupus nephritis. Biochem Biophys Res Comm 200: 893–898

    Article  PubMed  CAS  Google Scholar 

  65. Boutard V, Fouqueray B, Philippe C, Perez J, Baud L (1994) Fish oil supplementation and essential fatty acid deficiency reduce nitric oxide synthesis by rat macrophages. Kidney Int 46: 1280–1286

    Article  PubMed  CAS  Google Scholar 

  66. Eddy AA, Giachelli CM (1995) Renal expression of genes that promote interstitial inflammation and fibrosis in rats with protein-overload proteinuria. Kidney Int 47: 1546–1557

    Article  PubMed  CAS  Google Scholar 

  67. Khair-El-Din TA, Sicher SC, Vazquez MA, Wright WJ, Lu CY (1995) Docosahexaenoic acid, a major constituent of fetal serum and fish oil diets, inhibits IFNy-induced la-expression by murine macrophages in vitro. J Immunol 154: 1296–1306

    PubMed  CAS  Google Scholar 

  68. Grande JP, Walker HJ, Donadio JV, Dousa TP (1997) Omega-3 fatty acids inhibit mesangial cell proliferation in proliferative glomerulonephritis. J Invest Med 45: 279A

    Google Scholar 

  69. Border WA, Noble NA, Ketteler M (1995) TGF-beta: A cytokine mediator of glomerulosclerosis and a target for therapeutic intervention. Kidney Int 47: S59–S61

    Google Scholar 

  70. Grande JP (1997) Role of transforming growth factor-beta in tissue injury and repair. Proc Soc Exp Biol Med 214: 27–40

    PubMed  CAS  Google Scholar 

  71. Grande JP, Melder DC, Zinsmeister AR (1997) Modulation of collagen gene expression by cytokines: Stimulatory effect of transforming growth factor-ß1, with divergent effects of epidermal growth factor and tumor necrosis factor-a on collagen type I and collagen type IV. J Lab Clin Med 130: 476–486

    Article  PubMed  CAS  Google Scholar 

  72. Niemir ZI, Stein H, Noronha IL, Kruger C, Andrassy K, Ritz E, Waldherr R (1995) PDGF and TGF-beta contribute to the natural course of human IgA glomerulonephritis. Kidney Int 48: 1530–1541

    Article  PubMed  CAS  Google Scholar 

  73. Chandrasekar B, Troyer DA, Venkatraman JT, Fernandes G (1995) Dietary omega-3 lipids delay the onset and progression of autoimmune lupus nephritis by inhibiting transforming growth factor ß mRNA and protein expression. J Autoimmun 8: 381–393

    Article  PubMed  CAS  Google Scholar 

  74. Studer RK, Craven PA, DeRubertis FR (1997) Antioxidant inhibition of protein kinase C-signaled increases in transforming growth factor-beta in mesangial cells. Metabolism 46(8): 918–925

    Article  PubMed  CAS  Google Scholar 

  75. Nakamura T, Takahashi T, Fukui M et al (1995) Enalapril attenuates increased gene expression of extracellular matrix components in diabetic rats. J Am Soc Nephrol 5: 1492–1497

    CAS  Google Scholar 

  76. Thomazy V, Fesus L (1989) Differential expression of tissue transglutaminase in human cells: An immunohistochemical study. Cell Tissue Res 255: 215–224

    Article  PubMed  CAS  Google Scholar 

  77. Chini EN, Chini CCS, Bollinger C, Jougasaki M, Grande JP, Burnett JC, Dousa TP (1997) Cytoprotective effects of adrenomedullin in glomerular cell injury: Central role of cAMP signaling pathway. Kidney Int 52: 917–925

    Article  PubMed  CAS  Google Scholar 

  78. Eddy AA (1994) Experimental insights into the tubulointerstitial disease accompanying primary glomerular lesions. J Am Soc Nephrol 5: 1273–1287

    CAS  Google Scholar 

  79. Venkatraman JT, Chandrasekar B, Kim JD, Fernandes G (1994) Effects of n-3 and n-6 fatty acids on the activities and expression of hepatic antioxidant enzymes in autoimmune-prone NZBxNZW Fl mice. Lipids 29: 561–568

    Article  PubMed  CAS  Google Scholar 

  80. Morita Y, Nomura A, Yuzawa Y, Nishikawa K, Hotta N, Shimizu F, Matsuo S (1997) The role of complement in the pathogenesis of tubulointerstitial lesions in rat mesangial proliferative glomerulonephritis. J Am Soc Nephrol 8: 1363–1372

    PubMed  CAS  Google Scholar 

  81. Cartwright IJ, Pockley AG, Galloway JH, Greaves M, Preston FE (1985) The effects of dietary omega-3 polyunsaturated fatty acids on erythrocyte membrane phospholipids, erythrocyte deformability, and blood viscosity in healthy volunteers. Atherosclerosis 55: 267–281

    Article  PubMed  CAS  Google Scholar 

  82. Driss F, Vericel E, Lagarde M, Dechavanne M, Darcet P (1984) Inhibition of platelet aggregation and thromboxane synthesis after intake of small amount of eicosapentaenoic acid. Thromb Res 36: 389–396

    Article  PubMed  CAS  Google Scholar 

  83. Skeaff CM, Holub BJ (1988) The effect of fish oil consumption on platelet aggregation responses in washed human platelet suspensions. Thromb Res 51: 105–115

    Article  PubMed  CAS  Google Scholar 

  84. Phillipson BE, Rothrock DW, Connor WE, Harris WS, Illingworth DR (1985) Reduction of plasma lipids, lipoproteins, and apoproteins by dietary fish oils in patients with hypertriglyceridemia. N Engl J Med 312: 1210–1216

    Article  PubMed  CAS  Google Scholar 

  85. Clark WF, Parbtani A, Huff MW, Reid B, Holub BJ, Falardeau P (1989) Omega-3 fatty acid dietary supplementation in systemic lupus erythematosus. Kidney Int 36: 653–660

    Article  PubMed  CAS  Google Scholar 

  86. De Caterina R, Caprioli R, Giannessi D, Sicari R, Galli C, Lazzerini G, Bernini W, Carr L, Rindi P (1993) n-3 fatty acids reduce proteinuria in patients with chronic glomerular disease. Kidney Int 44: 843–850

    Article  PubMed  Google Scholar 

  87. Hobbs LM, Rayner TE, Howe PRC (1996) Dietary fish oil prevents the development of renal damage in salt-loaded stroke-prone spontaneously hypertensive rats. Clin Exp Pharmacol Physiol 23: 508–513

    Article  PubMed  CAS  Google Scholar 

  88. Prickett JD, Robinson DR, Steinberg AD (1981) Dietary enrichment with the polyunsaturated fatty acid eicosapentaenoic acid prevents proteinuria and prolongs survival in NZB X NZW F1 mice. J Clin Invest 68: 556–559

    Article  PubMed  CAS  Google Scholar 

  89. Prickett JD, Robinson DR, Steinberg AD (1983) Effects of dietary enrichment with eicosapentaenoic acid upon autoimmune nephritis in female NZB x NZW/F1 mice. Arthritis Rheum 26: 133–139

    Article  PubMed  CAS  Google Scholar 

  90. Robinson DR, Prickett JD, Makoul GT, Steinberg AD, Colvin RB (1986) Dietary fish oil reduces progression of established renal disease in (NZB x NZW)F1 mice and delays renal disease in BXSB and MRL/1 strains. Arthritis Rheum 29: 539–546

    Article  PubMed  CAS  Google Scholar 

  91. Hamazaki T, Tateno S, Shishido H (1984) Eicosapentaenoic acid and IgA nephropathy. Lancet 1: 1017–1018

    Article  PubMed  CAS  Google Scholar 

  92. Donadio JV, Bergstralh EJ, Offord KP, Spencer DC, Holley KE (1994) A controlled trial of fish oil in IgA nephropathy. N Engl J Med 331: 1194–1199

    Article  PubMed  Google Scholar 

  93. Donadio JV, Dart RA, Grande JP, Bergstralh EJ, Spencer DC (1997) Long-term treatment with fish oil reduces renal progression in patients with IgA nephropathy (IgAN). J Am Soc Nephrol 8: 85A

    Google Scholar 

  94. Bennett WM, Walker RG, Kincaid-Smith P (1989) Treatment of IgA nephropathy with eicosapentaenoic acid (EPA): A two year prospective trial. Clin Nephrol 31: 128–131

    PubMed  CAS  Google Scholar 

  95. Pettersson EE, Rekola S, Berglund L, Sundqvist KG, Angelin B, Diczfalusy U, Björkhem I, Bergstrom J (1994) Treatment of IgA nephropathy with omega-3-polyunsaturated fatty acids: A prospective, double-blind, randomized study. Clin Nephrol 41: 183–190

    PubMed  CAS  Google Scholar 

  96. Cheng IKP, Chan PCK, Chan MK (1990) The effect of fish-oil dietary supplement on the progression of mesangial IgA glomerulonephritis. Nephrol Dial Transplant 5: 241–246

    Article  PubMed  CAS  Google Scholar 

  97. Fung SM, Ferrill MJ, Norton LL (1997) Fish oil therapy in IgA nephropathy. Ann Pharmacother 31: 112–115

    PubMed  CAS  Google Scholar 

  98. Hogg RJ (1995) A randomized, placebo-controlled, multicenter trial evaluating alternate-day prednisone and fish oil supplements in young patients with IgA nephropathy. Am J Kidney Dis 26: 792–796

    Article  PubMed  CAS  Google Scholar 

  99. Donadio JV, Bergstralh EJ, Offord KP, Grande JP, Larson TS, Spencer DC. A prospective comparative study of two doses of OmacorTM in the treatment of patients with IgA nephropathy. In progress

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Anatomic Pathology, Department of Laboratory Medicine and Pathology and Division of Nephrology, Department of Internal Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN, 55905, USA

    Joseph P. Grande

  2. Division of Nephrology, Department of Internal Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN, 55905, USA

    James V. Donadio (Chair, Emeritus )

Authors
  1. Joseph P. Grande
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. James V. Donadio
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Division of Rheumatology, Albany Medical College, Albany, NY, 12208, USA

    Joel M. Kremer (Professor of Medicine, Head) (Professor of Medicine, Head)

Rights and permissions

Reprints and permissions

Copyright information

© 1998 Springer Basel AG

About this chapter

Cite this chapter

Grande, J.P., Donadio, J.V. (1998). n-3 Polyunsaturated fatty acids in the treatment of patients with IgA nephropathy. In: Kremer, J.M. (eds) Medicinal Fatty Acids in Inflammation. Progress in Inflammation Research. Birkhäuser, Basel. https://doi.org/10.1007/978-3-0348-8825-7_10

Download citation

  • DOI: https://doi.org/10.1007/978-3-0348-8825-7_10

  • Publisher Name: Birkhäuser, Basel

  • Print ISBN: 978-3-0348-9788-4

  • Online ISBN: 978-3-0348-8825-7

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation